More patients OK'd for cancer trials under Obamacare: study

July 20, 2017

(HealthDay)—The Affordable Care Act has enabled more privately insured patients to enroll in clinical trials for new cancer treatments, a new study contends.

Speedy approvals are important for patients who want to participate in , said study author Dr. David Hong. He's deputy chair of investigational therapeutics at the University of Texas MD Anderson Cancer Center.

Since 2000, Medicare, the publicly funded insurance program for seniors, has covered routine costs of clinical trial participation. But coverage for patients with private insurance differed by insurer and state, the researchers noted. Under the ACA, or Obamacare, however, private insurers had to cover "standard of care" costs of clinical trial participation as of 2014.

For this study, the researchers analyzed more than 2,400 patient referrals to the Clinical Center for Targeted Therapy at the MD Anderson Cancer Center in Houston. They found that insurer approval rates rose from about 85 percent before the ACA to about 95 percent after it took effect. Also, privately insured patients had fewer delays in receiving approval.

However, there were no significant changes in insurer approval rates or referral wait times for patients covered by Medicare or Medicaid, according to the study.

The results were published July 20 in the journal Clinical Cancer Research.

Hong said the fact that privately insured patients had fewer delays in receiving approval shows that the Affordable Care Act requirement directly benefited those patients.

"In a phase 1 trial, many patients are in a state of advanced disease, so a single day can matter a great deal to them," Hong said in a journal news release. Phase 1 trials are studies of a new drug first to involve people to test safety and watch for side effects.

"We are in a golden era of new drugs, but the only way to get them approved and available to patients is to get more people into clinical trials," he added.

Whatever happens to the ACA under the Trump administration, it's important to ensure patient access to clinical trials, Hong said.

"Clinical trials are crucially important in helping get drugs to the patients that need them," Hong added. "This study is one piece of evidence that the ACA is helping more get access to these ."

Explore further: Insurance approval rates for clinical trial participation rose under Affordable Care Act

More information: The U.S. National Cancer Institute has more on clinical trials.

Related Stories

Insurance approval rates for clinical trial participation rose under Affordable Care Act

July 20, 2017
Approval rates for privately insured patients seeking to enroll in oncology clinical trials increased after the passage of the Affordable Care Act.

Study: Costs may keep low-income patients from clinical trials

November 9, 2015
Cancer patients with lower incomes are a third less likely to be part of clinical trials that could help treat their disease than those whose annual income is at least $50,000, according to a new study.

New study questions clinical trial data for kidney cancer drugs

September 23, 2015
When prescribing newly approved drugs, physicians rely on data from clinical trials to understand the benefits and risks of those drugs for patients. But a study published in the Journal of Oncology Practice showed that for ...

Income affects oncology clinical trial participation

January 16, 2013
(HealthDay)—Oncology patients with lower income, even older patients with access to Medicare, are significantly less likely to participate in clinical trials, according to research published online Jan. 7 in the Journal ...

Expectations may not match reality among cancer patients in some early phase clinical trials

October 28, 2016
In a study of cancer patients considering whether they should participate in phase I clinical trials, a high percentage were willing to participate after discussions with clinical staff, but nearly half thought that their ...

Patients with lower income less likely to participate in clinical trials

October 15, 2015
Patients newly diagnosed with cancer were less likely to participate in clinical trials if their annual household income was below $50,000, according to an article published online by JAMA Oncology.

Recommended for you

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

An integrated approach to finding new treatments for breast cancer

December 12, 2018
Unraveling the complexity of cancer biology can lead to the identification new molecules involved in breast cancer and prompt new avenues for drug development. And proteogenomics, an integrated, multipronged approach, seems ...

Lethal combination: Drug cocktail turns off the juice to cancer cells

December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth—this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.